Relative prevalence and antimicrobial susceptibility of clinical isolates of Elizabethkingia species based on 16S rRNA gene sequencing

Mi Soon Han, Hyunsoo Kim, Yangsoon Lee, Myungsook Kim, Nam Su Ku, JunYong Choi, DongEun Yong, Seokhoon Jeong, Kyungwon Lee, Yunsop Chong

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Some of the previously reported clinical isolates of Elizabethkingia meningoseptica may be later named species of Elizabethkingia. We determined the accuracy of species identification (with two matrix-assisted laser desorption ionization-time of flight mass spectrometry [MALDI-TOF MS] systems and the Vitek 2 GN card), relative prevalence of three Elizabethkingia spp. in clinical specimens, and antimicrobial susceptibility of the species identified by 16S rRNA gene sequencing. Specimens for culture were collected from patients in a university hospital in Seoul, South Korea, between 2009 and 2015. All 3 Elizabethkingia spp. were detected in patients; among the 86 isolates identified by 16S rRNA gene sequencing, 17 (19.8%) were E. meningoseptica, 18 (20.9%) were Elizabethkingia miricola, and 51 (59.3%) were Elizabethkingia anophelis. Only the MALDI-TOF Vitek MS system with an amended database correctly identified all of the isolates. The majority (76.7%) of the isolates were from the lower respiratory tract, and 8 (9.3%) were from blood. Over 90% of E. meningoseptica and E. anophelis isolates were susceptible to piperacillin-tazobactam and rifampin. In contrast, all E. miricola isolates were susceptible to fluoroquinolones except ciprofloxacin. Further studies are urgently needed to determine the optimal antimicrobial agents for the treatment of infections due to each individual Elizabethkingia species.

Original languageEnglish
Pages (from-to)274-280
Number of pages7
JournalJournal of Clinical Microbiology
Volume55
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

rRNA Genes
Republic of Korea
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Fluoroquinolones
Rifampin
Ciprofloxacin
Anti-Infective Agents
Respiratory System
Mass Spectrometry
Lasers
Databases
Infection
Therapeutics
tazobactam drug combination piperacillin
Seoul

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)

Cite this

@article{38d72d7b2c3249aa97c6440dd8d0ca5a,
title = "Relative prevalence and antimicrobial susceptibility of clinical isolates of Elizabethkingia species based on 16S rRNA gene sequencing",
abstract = "Some of the previously reported clinical isolates of Elizabethkingia meningoseptica may be later named species of Elizabethkingia. We determined the accuracy of species identification (with two matrix-assisted laser desorption ionization-time of flight mass spectrometry [MALDI-TOF MS] systems and the Vitek 2 GN card), relative prevalence of three Elizabethkingia spp. in clinical specimens, and antimicrobial susceptibility of the species identified by 16S rRNA gene sequencing. Specimens for culture were collected from patients in a university hospital in Seoul, South Korea, between 2009 and 2015. All 3 Elizabethkingia spp. were detected in patients; among the 86 isolates identified by 16S rRNA gene sequencing, 17 (19.8{\%}) were E. meningoseptica, 18 (20.9{\%}) were Elizabethkingia miricola, and 51 (59.3{\%}) were Elizabethkingia anophelis. Only the MALDI-TOF Vitek MS system with an amended database correctly identified all of the isolates. The majority (76.7{\%}) of the isolates were from the lower respiratory tract, and 8 (9.3{\%}) were from blood. Over 90{\%} of E. meningoseptica and E. anophelis isolates were susceptible to piperacillin-tazobactam and rifampin. In contrast, all E. miricola isolates were susceptible to fluoroquinolones except ciprofloxacin. Further studies are urgently needed to determine the optimal antimicrobial agents for the treatment of infections due to each individual Elizabethkingia species.",
author = "Han, {Mi Soon} and Hyunsoo Kim and Yangsoon Lee and Myungsook Kim and Ku, {Nam Su} and JunYong Choi and DongEun Yong and Seokhoon Jeong and Kyungwon Lee and Yunsop Chong",
year = "2017",
month = "1",
day = "1",
doi = "10.1128/JCM.01637-16",
language = "English",
volume = "55",
pages = "274--280",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "1",

}

Relative prevalence and antimicrobial susceptibility of clinical isolates of Elizabethkingia species based on 16S rRNA gene sequencing. / Han, Mi Soon; Kim, Hyunsoo; Lee, Yangsoon; Kim, Myungsook; Ku, Nam Su; Choi, JunYong; Yong, DongEun; Jeong, Seokhoon; Lee, Kyungwon; Chong, Yunsop.

In: Journal of Clinical Microbiology, Vol. 55, No. 1, 01.01.2017, p. 274-280.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Relative prevalence and antimicrobial susceptibility of clinical isolates of Elizabethkingia species based on 16S rRNA gene sequencing

AU - Han, Mi Soon

AU - Kim, Hyunsoo

AU - Lee, Yangsoon

AU - Kim, Myungsook

AU - Ku, Nam Su

AU - Choi, JunYong

AU - Yong, DongEun

AU - Jeong, Seokhoon

AU - Lee, Kyungwon

AU - Chong, Yunsop

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Some of the previously reported clinical isolates of Elizabethkingia meningoseptica may be later named species of Elizabethkingia. We determined the accuracy of species identification (with two matrix-assisted laser desorption ionization-time of flight mass spectrometry [MALDI-TOF MS] systems and the Vitek 2 GN card), relative prevalence of three Elizabethkingia spp. in clinical specimens, and antimicrobial susceptibility of the species identified by 16S rRNA gene sequencing. Specimens for culture were collected from patients in a university hospital in Seoul, South Korea, between 2009 and 2015. All 3 Elizabethkingia spp. were detected in patients; among the 86 isolates identified by 16S rRNA gene sequencing, 17 (19.8%) were E. meningoseptica, 18 (20.9%) were Elizabethkingia miricola, and 51 (59.3%) were Elizabethkingia anophelis. Only the MALDI-TOF Vitek MS system with an amended database correctly identified all of the isolates. The majority (76.7%) of the isolates were from the lower respiratory tract, and 8 (9.3%) were from blood. Over 90% of E. meningoseptica and E. anophelis isolates were susceptible to piperacillin-tazobactam and rifampin. In contrast, all E. miricola isolates were susceptible to fluoroquinolones except ciprofloxacin. Further studies are urgently needed to determine the optimal antimicrobial agents for the treatment of infections due to each individual Elizabethkingia species.

AB - Some of the previously reported clinical isolates of Elizabethkingia meningoseptica may be later named species of Elizabethkingia. We determined the accuracy of species identification (with two matrix-assisted laser desorption ionization-time of flight mass spectrometry [MALDI-TOF MS] systems and the Vitek 2 GN card), relative prevalence of three Elizabethkingia spp. in clinical specimens, and antimicrobial susceptibility of the species identified by 16S rRNA gene sequencing. Specimens for culture were collected from patients in a university hospital in Seoul, South Korea, between 2009 and 2015. All 3 Elizabethkingia spp. were detected in patients; among the 86 isolates identified by 16S rRNA gene sequencing, 17 (19.8%) were E. meningoseptica, 18 (20.9%) were Elizabethkingia miricola, and 51 (59.3%) were Elizabethkingia anophelis. Only the MALDI-TOF Vitek MS system with an amended database correctly identified all of the isolates. The majority (76.7%) of the isolates were from the lower respiratory tract, and 8 (9.3%) were from blood. Over 90% of E. meningoseptica and E. anophelis isolates were susceptible to piperacillin-tazobactam and rifampin. In contrast, all E. miricola isolates were susceptible to fluoroquinolones except ciprofloxacin. Further studies are urgently needed to determine the optimal antimicrobial agents for the treatment of infections due to each individual Elizabethkingia species.

UR - http://www.scopus.com/inward/record.url?scp=85008420159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008420159&partnerID=8YFLogxK

U2 - 10.1128/JCM.01637-16

DO - 10.1128/JCM.01637-16

M3 - Article

VL - 55

SP - 274

EP - 280

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 1

ER -